On May 8, 2025, Tyra Biosciences reported its financial results for the first quarter ended March 31, 2025. The company announced that its BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) is now open for enrollment, with dosing expected to begin in the second quarter.
The company also initiated patient dosing in the SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC), marking the advancement of another pipeline candidate. As of March 31, 2025, Tyra Biosciences held $318.9 million in cash, cash equivalents, and marketable securities, providing a projected cash runway through at least 2027.
The net loss for the first quarter of 2025 was $28.147 million, compared to $18.192 million for the same period in 2024. Research and development expenses increased to $24.964 million from $17.203 million year-over-year, reflecting the ramp-up in clinical trial activities and manufacturing efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.